

Carbon Reduction Plan Template

Supplier name: Otsuka Pharmaceutical (U.K.) Ltd. (OPUK)

Publication date: 16 August 2024

Commitment to achieving Net Zero

Otsuka Holdings (Japan) has established a 2050 Environmental vision “Net Zero” with the aim of reducing the total environmental impact across all its business activities to zero. For more information about it, please refer to the Environment section of the Otsuka Holdings Sustainability page and the Environmental report 2023.

Otsuka Pharmaceutical entities in Europe (Otsuka Pharmaceutical Europe Ltd. and affiliates, including OPUK) have conducted their first carbon footprint analysis between Q3 2023 and Q2 2024. The organisation is now developing its carbon footprint reduction plan including carbon reduction targets.

Baseline Emissions Footprint

Baseline emissions are a record of the greenhouse gases that have been produced in the past and were produced prior to the introduction of any strategies to reduce emissions. Baseline emissions are the reference point against which emissions reduction can be measured.

| | |
|--|---------------------------------|
| Baseline Year: 2022 for Scopes 1, 2 and 3 | |
| Additional Details relating to the Baseline Emissions calculations. | |
| The first carbon footprint analysis has been conducted across Otsuka entities in Europe (Otsuka Pharmaceutical Europe Ltd. and affiliates) in 2023/2024 with the support of an external provider to ensure alignment with the Greenhouse gas Protocol (GHG). No previous reporting was published before. Emissions are reported on a calendar year basis (1st January – 31st December). Associated carbon reduction plan and reduction targets are currently under development and to be finalised by end of 2024. The information provided below for the emissions are only related to OPUK. | |
| Baseline year emissions: 2022⁴ | |
| EMISSIONS | TOTAL (tCO₂e) |
| Scope 1 | 17.39 t Co2 |

| | |
|---------------------------------------|--|
| Scope 2 | 53.44 t Co2 Calculated using the market-based method. Emissions calculated using the location-based method are 34.73 t CO ₂ . |
| Scope 3 (Included Sources) | <u>Sources included:</u> purchased goods & services (excluding raw materials and CMO energies emissions), Fuel and energy related activities, upstream transportation and distribution (excluding inbound logistics of packaging), waste generated in operations, business travel, employee commuting, end-of-life treatment of sold products. |
| Total Emissions | 294.88 t Co2 |

Current Emissions Reporting

| | |
|--|--|
| Reporting Year: 2024⁴ | |
| Note: Associated carbon reduction plan and reduction targets are currently under development and to be finalised by end of 2024. Reporting of the year 2024 is based upon the 2022 year. | |
| EMISSIONS | TOTAL (tCO_{2e}) |
| Scope 1 | 17.39 t Co2 |
| Scope 2 | 53.44 t Co2 Calculated using the market-based method. Emissions calculated using the location-based method are 34.73 t CO ₂ . |
| Scope 3 (Included Sources) | <u>Sources included:</u> purchased goods & services (excluding raw materials and CMO energies emissions), Fuel and energy related activities, upstream transportation and distribution (excluding inbound logistics of packaging), waste generated in operations, business travel, employee commuting, end-of-life treatment of sold products. |
| Total Emissions | 294.88 t Co2 |

Emissions reduction targets

OPUK is currently working with Otsuka Pharmaceutical Europe Ltd. and other affiliates located in Europe to define a carbon footprint reduction plan and reduction targets applicable across its activities, with the objective to have them defined by the end of 2024

Carbon Reduction Projects

OPUK is currently working with Otsuka Pharmaceutical Europe Ltd. and other affiliates located in Europe to define a carbon footprint reduction plan and reduction targets applicable across its activities and based on hotspots identified (e.g., business travels, inbound logistics, packaging, etc.) with the objective to have them defined by the end of 2024.

Some activities have been already implemented such as (but not limited too):

- Offices moved to Windsor for OPUK and Otsuka Pharmaceutical Europe Ltd., accessible via public transport,
- Flexible working offered to OPUK employees,
- Encouraging car sharing for company events and use of public transport,
- Initiatives under environmental aspects (e.g., sustainable coffee options, remove one-of use items in offices, recycled paper, etc.)

At global level, initiatives undertaken are highlighted within the Otsuka Holdings Sustainability page and the Environmental report 2023.

Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard¹ and uses the appropriate Government emission conversion factors for greenhouse gas company reporting².

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard³.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

Signed on behalf of the Supplier:

Ryan Gynne, OPUK Managing Director; Annabel O'Connor, General Counsel Europe

Date: August 2024

¹<https://ghgprotocol.org/corporate-standard>

²<https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

³<https://ghgprotocol.org/standards/scope-3-standard>

⁴ [Otsuka data on file](#)